CG
MRNS

Cutler Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Cutler Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,000
Closed -$2K – 6544
2021
Q2 		$2K Buy
+3,000
New +$48.3K ﹤0.01% 5131
2018
Q1 		– Sell
-700
Closed -$6K – 5405
2017
Q4 		$6K Buy
+700
New +$18.9K ﹤0.01% 3543

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Cutler Group's MRNS Position: Q3 2022 in Review

Cutler Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2022, closing a stake of 13,259 shares — an estimated $64K sold.

Cutler Group first reported a position in MRNS in Q4 2017 and held it in 18 quarters. The position peaked at $81K in Q1 2018. 69 funds tracked by Wall St. Rank hold MRNS as of Q3 2022.

  • Cutler Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 13,259 Marinus Pharmaceuticals, Inc shares in Q3 2022, an estimated $64K.
  • Cutler Group first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 18 quarters.
  • Cutler Group's Marinus Pharmaceuticals, Inc position peaked at $81K in Q1 2018.
  • 69 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.